Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new ...

Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).

These results correspond to an 80% reduction in the risk of death among patients surviving beyond five years.

Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising results from a novel BMS androgen receptor antagonist and degrader in ...

Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...